Study findings published Thursday by Johns Hopkins and New York University School of Medicine researchers indicate psychotherapy fueled by a hallucinogenic called psilocybin, the active ingredient in the mind-altering drug known as magic mushrooms, could reduce psychological illness and distress among patients with life-threatening diagnoses....
Psilocybin may help smokers quit the habit by giving them a mystical experience, according to an article in The Atlantic Monthly. In a Heffter-supported study at Johns Hopkins University, 12 of 15 subjects quit smoking after three sessions with the psychedelic substance. Lead researcher Dr....
New research by a team including Heffter board member Franz Vollenweider casts light on the well-known but little understood ability of psychedelics to produce spiritual experiences. The study, published in the journalPsychopharmacology, involved EEG recordings of 50 healthy volunteers who took a moderate dose of psilocybin....
A new episode of Deep Dive, a series on HuffPost Live devoted to drugs and religion, features interviews with two Heffter researchers–Roland Griffiths and Franz Vollenweider. Among other topics, Dr. Griffiths describes his pioneering research on psilocybin and mystical experience. Dr. Vollenweider offers insights on...
Heffter board member, Dr. Stephen Ross, has written a profoundly accessible article on the somber topic of dying. Dr. Ross addresses the medical communities’ odd reluctance  in dealing with death and the distress this further inflicts on patients. He discusses “bad death” and “good death” in...
